Filter Results:
(111)
Show Results For
- All HBS Web
(111)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
Show Results For
- All HBS Web
(111)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
Using the Crowd as an Innovation Partner
From Apple to Merck to Wikipedia, more and more organizations are turning to crowds for help in solving their most vexing innovation and research questions, but managers remain understandably cautious. It seems risky and even unnatural to push problems out to vast... View Details
W. Carl Kester
Carl Kester is a Baker Foundation Professor and the George Fisher Baker Jr. Professor of Business Administration, Emeritus at Harvard Business School. He is a member of the Finance Unit. He served as Deputy Dean for Academic Affairs (2006-2010), Chairman of the... View Details
- Web
Faculty & Advisors | MBA
director, Affini-T Therapeutics. Furthermore, he has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and... View Details
- 02 Jan 2024
- Research & Ideas
10 Trends to Watch in 2024
The lightning-fast ascent of generative AI isn’t the only sea change on the horizon for businesses in the new year. The global economy is in flux as war, climate change, trade issues, and infrastructure problems demand attention. Many companies continue to struggle to... View Details
Keywords: by Rachel Layne
- Web
Great American Business Leaders of the 20th Century - Leadership
P. Colt United States Rubber Company, 1892–1918 Herman Cone II Cone Mills Corporation, 1938–1950 John T. Connor Merck & Company, 1955–1964 Carle C. Conway Continental Can Company, 1926–1959 Willibald H. Conzen Schering-Plough Corporation,... View Details
- 30 Mar 2012
- HBS Seminar
Matthew W. Emmens, Executive Chairman,Vertex Pharmaceuticals
- Web
Latin America - Global
Merck and senior consultant at McKinsey & Co., serving as global Practice Manager for the Business Technology Office Health Care Practice. She holds a degree in economics from the Argentine Catholic University, an MBA from Harvard... View Details
- 09 Aug 2021
- Research & Ideas
OneTen: Creating a New Pathway for Black Talent
Financial resources don’t determine the quality of education, but it would be absurd to deny that money helps. "Adding to the challenge, 65 percent of Black college students are also juggling full-time jobs or families." Merck CEO Kenneth... View Details
- 27 Oct 2020
- Research & Ideas
Can Being the ‘Token’ Give Women and Minorities a Competitive Edge?
to Look Outward The Little Understood Problem Confronting Diverse Workplaces Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk What do great leaders do differently? Share your insights below. View Details
Keywords: by Danielle Kost
- 01 Feb 2001
- News
Advisory Boards Help HBS Assess and Attain Its Goals
development, administrative and organizational challenges, and strategic governance issues facing the School, the BDA plays an important role in offering both counsel and support. According to BDA chairman Raymond V. Gilmartin (MBA '68), chairman, president, and CEO of... View Details
- Web
Recruiting Partners - Health Care
McKesson Corporation MDLand Medical Consultants Network, Inc. MedImmune Medtronic, Inc. Memorial Sloan-Kettering Cancer Center Merck & Co., Inc. Millennium Medical Management LLC/Surgery Center of Viera Millipore Corporation Moderna... View Details
John T. Connor
Connor was a key leader in expanding Merck into international markets. He was an ardent supporter of research and development that enabled Merck to produce a series of successful pharmaceutical applications.... View Details
Keywords: Healthcare
Raymond V. Gilmartin
Gilmartin increased the stock price of Merck & Company fourfold during his first four years as head of the company. Gilmartin has focused the company’s research endeavors on therapies which can benefit large populations. He also... View Details
Keywords: Healthcare
John J. Horan
Through heavy investments in research and development, Horan led Merck to become the leading U.S.-based manufacturer of prescription drugs in the world. Under Horan’s leadership, Merck doubled their spending... View Details
Keywords: Healthcare
- 01 Jan 2002
- News
Raymond V. Gilmartin (MBA '68)
Chairman, President & Chief Executive Officer Merck & Co., Inc. Return to Alumni Achievement Awards main page Earlier Education Union College, 1963 B.S., Electrical Engineering Other Jobs Eastman Kodak Company, 1963-66 "I was the first... View Details
- 17 Dec 2020
- Research & Ideas
The 10 Most Popular Stories of 2020
reader interest in an interview with Merck CEO Ken Frazier, who talked candidly about prospects for COVID-19 vaccines and racism in the workplace. Here are our most popular articles, research papers, and social media posts of 2020. In the... View Details
Keywords: by Dina Gerdeman
Henry W. Gadsden
Gadsden presided over a massive period of growth for Merck & Company. A strong believer in the power of research and development, he increased spending in this area four fold during his tenure – from $32 million to $125 million. Under... View Details
Keywords: Healthcare
P. Roy Vagelos
Vagelos had an uncanny ability to turn scientific research into commercial blockbuster success. He is credited with rejuvenating Merck’s research efforts, culminating in the development of breakthrough applications for hypertension, heart disease, and cholesterol... View Details
Keywords: Healthcare
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
science-based research is something the heads of top biotech and pharmas learned long ago: There are few instant payoffs to please investors. Just ask Raymond Gilmartin, former chairman, president, and CEO of Merck & Co., who now... View Details
- 15 Apr 2014
- News
Bertarelli Foundation Gift Names Deans' Health & Life Sciences Challenge Prize
generations. In 2007, Serono was purchased by Merck KGaA. The company was subsequently known as Merck Serono SA. Since the sale of Serono, Bertarelli has focused on a number of private investment and... View Details